Novel inhaled combination powders for respiratory infections
- In: APSA EARLY CAREER RESEARCHER SYMPOSIUM on Tuesday, 15 April 2014, 16:00-17:30
- At: PSWC, Melbourne (Australia) (2014)
- Type: Presentation
- By: ZHOU, Qi (Tony) (The University of Sydney, Faculty of Pharmacy, Sydney, Australia)
- Co-author(s): Gengenbach, Thomas (CSIRO Materials Science and Engineering, Melbourne, Australia)
Denman, John (University of South Australia, Adelaide, Australia)
Yu, Heidi (Monash University, Melbourne, Australia)
Li, Jian (Monash University, Melbourne, Australia)
Chan, Hak-Kim (The University of Sydney, Sydney, Australia)
Background: For many respiratory infections caused by multidrug-resistant Gram-negative bacteria, colistin is the only effective antibiotics despite its nephrotoxicity. Inhaled therapy of colistin with a synergistic antimicrobial component of rifampicin may offer better therapeutic efficacy and reduce adverse effects.
Aims: To develop a novel.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.